Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

CRISPR and CRISPR-Associated Gene Market Set to Surge to $20 Billion by 2035, Fueled by Technological Breakthroughs and Biotech Investments The global CRISPR and CRISPR-Associated Gene Market Size is ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended ...

Indian American physician-scientist and business executive Reshma Kewalramani, the CEO of Vertex Pharmaceuticals, has been ...

The Food and Drug Administration has approved the world’s first medicine based on CRISPR gene-editing technology, a ...

Learn more about whether Amarin Corporation plc or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

The Motley Fool has positions in and recommends AbbVie, Bristol Myers Squibb, CRISPR Therapeutics, Gilead Sciences, Merck, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals. The Motley Fool ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals ... developed with CRISPR Therapeutics, offers a revolutionary ...